Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance

Patil, Yogesh; Sadhukha, Tanmoy; Ma, Likun; Panyam, Jayanth

doi:10.1016/j.jconrel.2009.01.021

Cited by 292 publications

(176 citation statements)

References 55 publications

Supporting

Mentioning

166

Contrasting

Order By: Relevance

“…Moreover, decoration of nanocarriers with targeting moieties overcomes the multiple-drug resistance (MDR), using peptides, [76][77][78][79][80] and avoids the limitations of passive targeting, since the EPR effect is not produced in certain hypovascular tumors [81,82] and the permeability of blood vessels can vary in a single tumor [83]. Active targeting nanocarriers are able to increase by many folds the antitumor efficacy compared to untargeted carriers [84].…”

Section: Reprinted By Permission From Macmillan Publishers Ltd: [Natumentioning

confidence: 99%

“…Moreover, in vivo studies in mice with 4T1 breast carcinoma that overexpresses the biotin receptor revealed that this biotin functionalized HSA nanoparticles enhanced the methotrexate antitumor efficacy and reduced its toxic effects compared to non-targeted nanoparticles or the free drug, decreasing the tumor volume and increasing the survival of the animals. Patil et al [80] used PLGA nanoparticles to achieve the simultaneous targeted delivery of an anticancer drug, paclitaxel, and tariquidar, an inhibitor of P-glycoprotein, to drug-resistant tumors, using also biotin as targeting ligand. These dual agent nanoparticles showed an enhanced cytotoxicity in vitro, compared to the same formulation loaded with paclitaxel alone, since they produced an increased accumulation of the drug in the drug-resistant cells due to the inhibition of Pglycoprotein.…”

Section: Biotin-based Targetingmentioning

confidence: 99%

See 1 more Smart Citation

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,383

754

View full text Add to dashboard Cite

Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vasculatization and, in time, adquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastasic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, like the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic Código de campo cambiado

show abstract

Section: Reprinted By Permission From Macmillan Publishers Ltd: [Natumentioning

confidence: 99%

Section: Biotin-based Targetingmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,383

754

View full text Add to dashboard Cite

show abstract

“…Particle size and zeta potential (Patil et al, 2009) Hydrodynamic diameter and zeta potential of nanoparticles were determined using Zetasizer Nano ZS 90 dynamic light scattering equipment (Malvern Instruments Ltd. UK). Nanoparticles (~1 mg/mL) were dispersed in distilled water using sonication prior to particle size and zeta potential determinations.…”

Section: Characterization Of Nanoparticlesmentioning

confidence: 99%

Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits

Ahmed¹,

Konwar²,

Sengupta³

2015

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

In this study, we prepared atorvastatin calcium (AVST) loaded chitosan nanoparticles to improve the oral bioavailability of the drug. Nanoparticles were prepared by solvent evaporation technique and evaluated for its particle size, entrapment efficiency, zeta potential, in vitro release and surface morphology by scanning electron microscopy (SEM). In addition, the pharmacokinetics of AVST from the optimized formulation (FT5) was compared with marketed immediate release formulation (Atorva ® ) in rabbits. Particle size of prepared nanoparticles was ranged between 179.3 ± 7.12 to 256.8 ± 8.24 nm with a low polydispersity index (PI) value. Zeta potential study showed that the particles are stable with positive values between 13.03 ± 0.32 to 46.90 ± 0.49 mV. FT-IR studies confirmed the absence of incompatibility of AVST with excipient used in the formulations. In vitro release study showed that the drug release was sustained for 48 h. Results of pharmacokinetics study showed significant changes in the pharmacokinetic parameter (2.2 fold increase in AUC) of the optimized formulation as compared to marketed formulation (Atorva ® ). Thus, the developed nanoparticles evidenced the improvement of oral bioavailability of AVST in rabbit model. Uniterms:Atorvastatin calcium/oral bioavailability/experimental study. Atorvastatin calcium/in vitro release. Atorvastatin calcium/pharmacokinetics. Nanoparticles/drugs bioavailability.No presente estudo, preparamos nanopartículas de quitosana com atorvastatina cálcica (AVST) para melhorar a biodisponibilidade oral do fármaco. As nanopartículas foram preparadas pela técnica de evaporação de solvente, avaliando-se a granulometria, a eficiência de encapsulamento, o potencial zeta, a liberação in vitro e a morfologia da superfície, por meio da microscopia eletrônica de varredura (MEV). Além disso, a farmacocinética da formulação otimizada de AVST (FT5) foi comparada com a formulação comercial, de liberação imediata, comercializada (Atorva®), em coelhos. O tamanho das das nanopartículas variou na faixa de 179,3 a 256,8 ± 7,12 ± 8,24 nm, com baixo índice polidispersibilidade (PI). O estudo do potencial Zeta mostrou que as partículas são estáveis, com valores positivos entre 13,03 ± 0,32 a 46,90 ± 0,49 mV. Os estudos de FT-IR confirmaram a ausência de incompatibilidade de AVST com o excipiente utilizado nas formulações. O estudo de liberação in vitro mostrou que liberação sustentada do fármaco por 48 horas. Os resultados do estudo farmacocinético mostraram alterações significativas nos parâmetros (aumento de 2,2 vezes na ASC) da formulação otimizada em relação à comercializada (Atorva® ). Assim, o desenvolvimento de nanopartículas evidenciou a melhora da biodisponibilidade oral de AVST em coelhos.Uniterms: Atorvastatina cálcica/biodisponibilidade oral/estudo experimental. Atorvastatina cálcica/ liberação in vitro. Atorvastatina cálcica/farmacocinética. Nanopartículas/biodisponibilidade de fármacos.

show abstract

“…For example, the first ABC transporter inhibitor to be identified is ABCB1 (P-gp) inhibitor named verapamil, which is often used as control in side population assay to block efflux of Hoechst 33342 dye [131]. Other novel ABC transporter inhibitors that have been developed include methylene blue [132], MS-209 [133], VX-710 [134], tariquidar and others [135,136]. However, first generation ABC transporter inhibitors (verapamil, cyclosporine) failed in clinical trials on account of their low binding efficacy of the drug to its target, requiring the drug to be used in high doses that cause cytotoxicity [137].…”

Section: Cscs and Microenvironmentmentioning

confidence: 99%

Cancer Stem Cells: Formidable Allies of Cancer

Deshpande

Rangarajan

2015

Indian J Surg Oncol

View full text Add to dashboard Cite

Cancer stem cells (CSC) represent the subpopulation of cells within a tumour showing two fundamental properties of stem cells -self-renewal (the ability to make more of their own kind) and differentiation (the ability to generate diverse cell types present within a tissue). The CSC hypothesis posits that CSCs play an important role in tumour initiation, maintenance and progression. Furthermore, owing to their intrinsic drug resistance, they remain refractory to currently used therapy, thereby contributing to tumour relapse. Thus, targeting or taming CSCs can lead to more effective cancer treatment in the coming decades. In this review, we will discuss about the origin of CSC hypothesis, evidence showing their existence, clinical relevance and translational significance.

show abstract

Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance

Cited by 292 publications

References 55 publications

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Atorvastatin calcium loaded chitosan nanoparticles: in vitro evaluation and in vivo pharmacokinetic studies in rabbits

Cancer Stem Cells: Formidable Allies of Cancer

Contact Info

Product

Resources

About